Stockreport

Exscientia Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers

Exscientia Plc - American Depositary Shares  (EXAI) 
PDF Clinical data builds upon body of evidence suggesting EXS-21546 is a highly potent and selective A2AR antagonist with low CNS exposureExscientia anticipates initiating P [Read more]